跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19,024 条关于
“PI3K/AKT/mTOR (PAM) pathway”
全部
19,024
临床试验
10,921
药物
1,162
机构
172
资讯
6,769
上个月
Evexta Bio and Roche Ink Clinical Collaboration to Evaluate Rupitasertib Plus Giredestrant in ESR1-Mutated Metastatic Breast Cancer
去年
Celcuity Secures Patent Extension for Gedatolisib Through 2042, Strengthening Breast Cancer Drug Portfolio
7个月前
Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR
去年
Disitamab Vedotin Shows Promising Activity in HER2-Expressing Metastatic Breast Cancer with PAM Pathway Abnormalities
11个月前
HUTCHMED Unveils First-in-Class HMPL-A251 Antibody-Targeted Therapy Conjugate with Superior Efficacy Against HER2-Positive Cancers
去年
Celcuity Secures $500 Million Credit Facility Following Positive Phase 3 Data for Gedatolisib in Advanced Breast Cancer
去年
Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results
去年
Ryvu Therapeutics Discovers Synergistic mTOR-AKT Inhibitor Combination for Colorectal Cancer Treatment
去年
Gedatolisib Shows Promising 77-Month Overall Survival in Advanced Breast Cancer Phase 1b Trial
11个月前
Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers
第 1 页，共 677 页
上一页
下一页
